SUBSCRIBE
SUBSCRIBE
News   Drug Development

Protalix Biotherapeutics, Inc. Plans Human Clinical Tests of Medication for Rare Fabry’s Disease

March 24, 2011 | 
1 min read
Bloomberg -- Protalix BioTherapeutics Ltd., an Israeli biotechnology company, plans to start clinical trials of a drug treating Fabry disease this year and a medication against rheumatoid arthritis in early 2012.
Preclinical
MORE ON THIS TOPIC
Focal seizure. Vector illustration of human brain and electroencephalograhy or EEG originating from temporal lobe.
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Layoffs
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees
September 11, 2025
 · 
1 min read
 · 
Tristan Manalac
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Immunology and inflammation
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
September 10, 2025
 · 
2 min read
 · 
Tristan Manalac